glucagon

Also known as hyperglycemic factor and hyperglycemic-glycogenolytic factor.

Latest news on glucagon

12 November 2026
Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.

9 November 2026
Merck reports positive Phase 2b efinopegdutide data in MASH with F2–F3 fibrosis

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.

5 November 2026
Lilly showcases retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026

Phase 3 TRIUMPH trials showed retatrutide cut knee pain by up to 75.8% with some patients pain‑free; TOGETHER‑PsA found ixekizumab plus tirzepatide raised ACR50 to 43.7% at 52 weeks.

28 October 2026
Boehringer Ingelheim reports survodutide meets cardiovascular safety endpoint

The Phase III trial found no increased risk of major cardiovascular events versus placebo, alongside improvements in weight, blood pressure and waist circumference.

28 October 2026
Lilly’s retatrutide outperforms Ozempic 2 mg in A1C and weight loss in Phase 3 head‑to‑head

At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.

16 October 2026
EMA recommends Eli Lilly’s oral GLP-1 Foundayo (orforglipron) for weight management and type 2 diabetes

Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.

1 October 2026
Boehringer Ingelheim reports Phase III survodutide results in obesity and type 2 diabetes

At 76 weeks, weight loss reached 13.1%, HbA1c fell by up to 1.21%, and gastrointestinal events led 18% of treated participants to discontinue.

29 September 2026
Lilly retatrutide shows large weight loss and A1C reductions in TRIUMPH-2

Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.

23 July 2026
Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3

First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.

7 June 2026
Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.